A 48-year-old woman from Delhi presents with a 3-year history of progressive joint pain and swelling affecting her hands, wrists, and knees. Morning stiffness lasts 2 hours. Examination reveals symmetrical polyarthritis with warmth and tenderness. ESR is 68 mm/hr, CRP is 12 mg/dL. Rheumatoid factor is positive (1:320). X-rays of hands show periarticular osteopenia and early erosions. Which of the following best describes the chronic inflammatory mechanism driving joint destruction in this condition?

Question

Accepted Answer

D. Th17 cell-mediated recruitment of osteoclasts via RANKL signaling, with TNF-α and IL-6 amplifying synovial inflammation. ## Diagnosis: Rheumatoid Arthritis (RA)

The clinical picture (symmetrical polyarthritis, morning stiffness >1 hour, RF positive, elevated acute phase reactants, periarticular osteopenia, erosions) is diagnostic of RA—a chronic autoimmune inflammatory arthropathy.

## Pathologic Mechanism of Joint Destruction in RA

**Key Point:** RA is primarily a **Th17-driven, TNF-α/IL-6-amplified chronic inflammation** with osteoclast activation via RANKL, NOT simple antibody-mediated lysis.

### The Pathogenic Sequence

```mermaid
flowchart TD
  A[Genetic predisposition + Environmental trigger]:::outcome --> B[Loss of tolerance to citrullinated proteins]
  B --> C[Th17 cell differentiation via IL-23 + IL-6]
  C --> D[Th17 cells produce IL-17, IL-22, TNF-α]
  D --> E[Synovial fibroblasts + macrophages activated]
  E --> F[Increased TNF-α, IL-6, IL-8, GM-CSF]
  F --> G[Neutrophil recruitment to synovium]
  G --> H[Osteoclast precursor recruitment via RANKL]
  H --> I[Osteoclast activation and bone resorption]
  I --> J[Cartilage degradation by MMPs]
  J --> K[Periarticular osteopenia and erosions]:::urgent
```

### Key Inflammatory Cytokines in RA

| Cytokine | Source | Effect |
|----------|--------|--------|
| **TNF-α** | Macrophages, Th17 cells | Synovial inflammation, osteoclast activation, endothelial activation |
| **IL-6** | Fibroblasts, macrophages | Systemic inflammation (↑ ESR, CRP), B cell activation, Th17 differentiation |
| **IL-17** | Th17 cells | Neutrophil recruitment, fibroblast activation, RANKL induction |
| **RANKL** | Th17 cells, fibroblasts | **Direct osteoclast activation** (key to bone erosion) |
| **MMPs** | Synovial fibroblasts, neutrophils | Cartilage matrix degradation |

**High-Yield:** The **RANKL–RANK axis** is the critical link between immune inflammation and bone destruction. RANKL (receptor activator of NF-κB ligand) is produced by Th17 cells and activated fibroblasts, binding to RANK on osteoclast precursors to drive their differentiation and activation.

### Why Erosions Form (Not Just Inflammation)

1. **Pannus formation** → Synovial hyperplasia with aggressive fibroblasts at cartilage–bone interface
2. **Osteoclast activation** → RANKL-driven osteoclastogenesis → bone resorption
3. **MMP release** → Collagenase and gelatinase degrade cartilage matrix
4. **Result** → Periarticular osteopenia (early) → marginal erosions (later)

**Clinical Pearl:** Anti-TNF and anti-IL-6 biologics (infliximab, adalimumab, tocilizumab) slow erosion progression by blocking these amplification loops. This confirms TNF-α and IL-6 are central to pathology, not peripheral.

## Why This Is NOT Other Mechanisms

**Mnemonic:** **TRAIL** = **T**h17 + **R**ANKL + **A**mplification (TNF/IL-6) + **I**nflammation + **L**oss of tolerance

| Mechanism | RA Fit | Why Not |
|-----------|--------|--------|
| **Th17 + RANKL** | ✓ Explains erosions + synovitis | Primary pathogenic axis |
| **Antibody + complement** | Partial (RF present, but not primary driver) | Complement activation is secondary; erosions are Th17-RANKL driven |
| **Immune complex vasculitis** | ✗ (RA is synovitis, not vasculitis) | Vasculitis occurs in severe RA (rheumatoid nodules), not primary mechanism |
| **Type I hypersensitivity** | ✗ (acute, IgE-mediated) | RA is chronic, Th17-mediated, not IgE |

Answer

A. Antibody-mediated complement activation leading to direct cartilage lysis and synovial necrosis

Answer

B. Type I hypersensitivity with mast cell infiltration of synovium and histamine-mediated inflammation

Answer

C. Immune complex deposition in synovial vessels causing vasculitis and ischemic joint necrosis

Explanation

Diagnosis: Rheumatoid Arthritis (RA)

Pathologic Mechanism of Joint Destruction in RA

The Pathogenic Sequence

Key Inflammatory Cytokines in RA

Why Erosions Form (Not Just Inflammation)

Why This Is NOT Other Mechanisms

Practice similar questions

Join our NEET PG community

Cytokine	Source	Effect
TNF-α	Macrophages, Th17 cells	Synovial inflammation, osteoclast activation, endothelial activation
IL-6	Fibroblasts, macrophages	Systemic inflammation (↑ ESR, CRP), B cell activation, Th17 differentiation
IL-17	Th17 cells	Neutrophil recruitment, fibroblast activation, RANKL induction
RANKL	Th17 cells, fibroblasts	Direct osteoclast activation (key to bone erosion)
MMPs	Synovial fibroblasts, neutrophils	Cartilage matrix degradation

Mechanism	RA Fit	Why Not
Th17 + RANKL	✓ Explains erosions + synovitis	Primary pathogenic axis
Antibody + complement	Partial (RF present, but not primary driver)	Complement activation is secondary; erosions are Th17-RANKL driven
Immune complex vasculitis	✗ (RA is synovitis, not vasculitis)	Vasculitis occurs in severe RA (rheumatoid nodules), not primary mechanism
Type I hypersensitivity	✗ (acute, IgE-mediated)	RA is chronic, Th17-mediated, not IgE